ALNY PDUFA decision: a positive outcome, +10.5%

On November 20, 2019, Alnylam Pharmaceuticals, Inc. reached its PDUFA decision. The result was a positive outcome, and the stock moved +10.5% in the window around the event. It had already run +6.1% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.